Better Health for All

Invivyd's core business is dedicated to developing antibody-based therapies for infectious diseases, with its primary product, Pemgarda, providing a 70% risk reduction in symptomatic COVID-19 for immunocompromised individuals.

The company also has a new pipeline program focused on a monoclonal antibody treatment for measles. No revenue is generated from products with negative health outcomes. Pemgarda is covered by Medicare and Medicaid without cost sharing, and a Patient Savings Program offers up to $250 per dose and $1,000 per year, with additional financial assistance available through Invivyd Care. The product targets immunocompromised adults and adolescents (12+ years, 88+ lbs) who may not adequately respond to COVID-19 vaccination, a vulnerable population. However, clinical trial data for Pemgarda showed 4 cases of anaphylaxis among 623 participants, which translates to a high adverse event rate of approximately 6,420 per million users. Common adverse events (incidence ≥2%) also include infusion-related reactions, upper respiratory tract infection, viral infection, flu-like illness, fatigue, headache, and nausea. While information on risks and benefits is provided in fact sheets and a Fact Sheet for Healthcare Providers, including a boxed warning for anaphylaxis, the FDA declined an expansion of Pemgarda's Emergency Use Authorization (EUA) for treatment of mild-to-moderate COVID-19 due to a perceived need for superior antiviral activity, not just equivalent. The company has initiated a first-in-human clinical trial for VYD2311, a next-generation mAb candidate for COVID-19. Pemgarda received an EUA from the FDA for COVID-19 prevention, demonstrating a response to a global health crisis.

Fair Money & Economic Opportunity

Invivyd, Inc. is a biotechnology company focused on developing antibody-based therapies. Its core business does not involve lending, insurance, or other financial services to consumers. While the company offers a Patient Savings Program to assist eligible commercially insured patients with medication costs,

this is a patient support service for healthcare access, not a financial product or service as defined by the rubric. Therefore, all KPIs related to financial products, services, and their impact on economic opportunity for underserved populations are not applicable, resulting in a score of 0 for all relevant KPIs.

Fair Trade & Ethical Sourcing

No specific, concrete evidence was found in the provided articles to assess Invivyd, Inc. against any of the KPIs for the 'Fair Trade & Ethical Sourcing' value. The articles did not contain information regarding fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, high-risk materials spend, or supplier diversity spend.

Information found in Article 3 pertained to internal employee conduct and policies, not supplier-related ethical sourcing practices.

Honest & Fair Business

Invivyd elected two new independent directors to its Board of Directors on May 21, 2024.

With a current board size of seven, this indicates that approximately 28.57% of the board members are independent.

Kind to Animals

The company conducts "in vivo" studies and tests in "animal models" to demonstrate safety and efficacy.

It seeks to streamline nonclinical toxicology studies where possible, with the intention of reducing dependence on animal studies, which aligns with the FDA’s position. The company's policy prohibits discretionary testing, but legal mandates still override alternatives. While there is increasing industry attention on animal-free antibody discovery technologies and various alternative methods exist, the evidence does not specify the extent to which Invivyd, Inc. currently employs these non-animal methods for its own product safety and efficacy testing.

No War, No Weapons

The provided articles explicitly state that they do not contain any data relevant to assessing Invivyd, Inc. (IVVD.US) against the 'No War, No Weapons' ethical value.

No specific, concrete information was found regarding arms or defense contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any other conflict-related activities. Therefore, no KPIs can be scored based on the available evidence.

Planet-Friendly Business

No specific, quantitative, or concrete evidence regarding Invivyd, Inc.'s environmental performance, targets, or initiatives could be found in the provided articles.

The available documents either state general policies and commitments to environmental compliance without providing measurable outcomes or explicitly indicate a lack of sustainability data for all relevant metrics.

Respect for Cultures & Communities

The provided article is Invivyd's Privacy Policy, which details data collection, usage, and disclosure practices.

The document explicitly states that it contains no data relevant to the company's respect for cultures and communities. Therefore, no evidence is available to assess Invivyd against any of the specified KPIs for this ethical value.

Safe & Smart Tech

Invivyd, Inc.'s privacy policy states that users have rights to access, delete, and transfer their data, and can opt-out of promotional emails.

The policy also indicates compliance with applicable laws and regulations, specifically mentioning Nevada data protection law.